Avalo Therapeutics (AVTX) announced the appointment of Kevin Lind to its Board of Directors. He most recently served as President, CEO, and Board Member of Longboard Pharmaceuticals.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics price target raised to $25 from $15 at H.C. Wainwright
- Oppenheimer buyers of Avalo Therapeutics ahead of lutikizumab data
- 3 Best Stocks to Buy Now, 9/12/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 9/5/2025, According to Top Analysts
- Buy Rating for Avalo Therapeutics Driven by Promising AVTX-009 Development and Market Potential